Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:CLRB NASDAQ:PRPH NASDAQ:SBPH NASDAQ:UMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.41-6.3%$2.26$1.32▼$381.10$4.66M5.771.56 million shs3.23 million shsCLRBCellectar Biosciences$5.19+1.2%$4.87$4.11▼$67.50$16.54M0.52211,098 shs11,196 shsPRPHProPhase Labs$0.44+2.0%$0.37$0.22▼$2.69$18.32M-0.786.44 million shs112,670 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AUMRXCogent Biosciences$12.54+1.0%$10.50$0.29▼$3.72$532.56M3.931.22 million shs1.14 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+4.17%-1.96%-25.00%-70.76%-99.98%CLRBCellectar Biosciences-0.39%-3.02%+18.20%-53.21%-91.78%PRPHProPhase Labs+1.02%-15.67%+24.33%+18.53%-81.90%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$1.41-6.3%$2.26$1.32▼$381.10$4.66M5.771.56 million shs3.23 million shsCLRBCellectar Biosciences$5.19+1.2%$4.87$4.11▼$67.50$16.54M0.52211,098 shs11,196 shsPRPHProPhase Labs$0.44+2.0%$0.37$0.22▼$2.69$18.32M-0.786.44 million shs112,670 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/AUMRXCogent Biosciences$12.54+1.0%$10.50$0.29▼$3.72$532.56M3.931.22 million shs1.14 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+4.17%-1.96%-25.00%-70.76%-99.98%CLRBCellectar Biosciences-0.39%-3.02%+18.20%-53.21%-91.78%PRPHProPhase Labs+1.02%-15.67%+24.33%+18.53%-81.90%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%UMRXCogent Biosciences-1.97%-2.13%+4.37%+62.86%+16.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.0015,589,935.59% UpsideCLRBCellectar Biosciences 2.50Moderate Buy$375.007,119.87% UpsidePRPHProPhase Labs 0.00N/AN/AN/ASBPHSpring Bank Pharmaceuticals 0.00N/AN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, PRPH, UMRX, CLRB, and SBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025CLRBCellectar BiosciencesRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M1.49N/AN/A$65.21 per share0.02CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/APRPHProPhase Labs$6.77M2.72N/AN/A$0.25 per share1.77SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AUMRXCogent Biosciences$22.50M23.67N/AN/A$1.04 per share12.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$19.91N/AN/AN/AN/A-486.67%-150.57%11/17/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/AUMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest APVO, PRPH, UMRX, CLRB, and SBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLRBCellectar Biosciences-$3.60-$3.39+$0.21-$3.39N/AN/A8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 million8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.272.27CLRBCellectar BiosciencesN/A2.152.15PRPHProPhase Labs0.200.960.93SBPHSpring Bank PharmaceuticalsN/A5.115.11UMRXCogent Biosciences0.182.902.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CLRBCellectar Biosciences16.41%PRPHProPhase Labs9.45%SBPHSpring Bank Pharmaceuticals17.17%UMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%CLRBCellectar Biosciences5.04%PRPHProPhase Labs9.60%SBPHSpring Bank Pharmaceuticals12.70%UMRXCogent Biosciences31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableCLRBCellectar Biosciences103.19 million3.03 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableAPVO, PRPH, UMRX, CLRB, and SBPH HeadlinesRecent News About These CompaniesCogent Biosciences price target raised to $20 from $17 at GuggenheimAugust 25, 2025 | msn.comCogent Biosciences Rated as a Buy at Citi on Robust PipelineJuly 25, 2025 | msn.comCogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz SurgesJuly 9, 2025 | msn.comCogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: AnalystJuly 8, 2025 | benzinga.comCogent Biosciences, Inc. Announces Underwritten Public Offering of $150 Million in Common StockJuly 8, 2025 | quiverquant.comQCogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA PlansJuly 8, 2025 | biospace.comBStudy results boost Cogent’s case for rare disease drugJuly 8, 2025 | biopharmadive.comBCogent Biosciences Shares Rise After Mastocytosis Treatment Reaches Primary Endpoint in Recent StudyJuly 7, 2025 | marketwatch.comCogent’s phase 3 hits primary endpoint, building case for filing to challenge Blueprint’s AyvakitJuly 7, 2025 | fiercebiotech.comFCogent Biosciences Jumps 10% After Bezuclastinib Trial Delivers Strong ResultsJuly 7, 2025 | msn.comCogent surges as bezuclastinib meets key goal in phase 2 mastocytosis trialJuly 7, 2025 | msn.comCogent Biosciences drug improves symptoms of chronic immune disorder, study results showJuly 7, 2025 | statnews.comSCogent Biosciences Reports Positive SUMMIT Trial Results for Bezuclastinib in Non-Advanced Systemic Mastocytosis, Prepares for FDA NDA SubmissionJuly 7, 2025 | quiverquant.comQCogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib LaunchJune 11, 2025 | quiverquant.comQWhy Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comCogent Biosciences Advances with Promising Clinical TrialsMay 6, 2025 | tipranks.comIs Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comCogent Biosciences (COGT): Among the Most Promising Penny Stocks According to AnalystsApril 20, 2025 | insidermonkey.comIs Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comCogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, PRPH, UMRX, CLRB, and SBPH Company DescriptionsAptevo Therapeutics NASDAQ:APVO$1.41 -0.09 (-6.27%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Cellectar Biosciences NASDAQ:CLRB$5.19 +0.06 (+1.25%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.ProPhase Labs NASDAQ:PRPH$0.44 +0.01 (+1.77%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Spring Bank Pharmaceuticals NASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
